Selected article for: "ANOVA analysis and statistical analysis"

Title: 2016 ACVIM Forum Research Abstract Program
  • Document date: 2016_5_31
  • ID: 2y1y8jpx_10
    Snippet: Results from this study indicate that the severity of MMVD or the presence of pulmonary hypertension did not negatively affect lifespan after bronchial stent placement. As such, moderate to severe MMVD and the presence of pulmonary hypertension should not be viewed as exclusion criteria when assessing candidates for possible bronchial stenting. Prospective studies should be conducted to further investigate the clinical benefit of bronchial stenti.....
    Document: Results from this study indicate that the severity of MMVD or the presence of pulmonary hypertension did not negatively affect lifespan after bronchial stent placement. As such, moderate to severe MMVD and the presence of pulmonary hypertension should not be viewed as exclusion criteria when assessing candidates for possible bronchial stenting. Prospective studies should be conducted to further investigate the clinical benefit of bronchial stenting in dogs with severe bronchial collapse. Dogs with naturally acquired tricuspid regurgitation (TR) were studied prospectively. All dogs had degenerative valve disease. Target variables were acquired during 4 study periods (dogs in lateral recumbency or standing, after a 6-minute walk test and after sedation [0.25 mg/kg butorphanol, IM]), and by two different observers. Heart rate (HR), TR flow velocity (TRFV), PVR, estimates of right atrial pressure, stroke volume, cardiac output, and 23 other variables were quantified. Statistical methods included repeated-measures ANOVA and mixed model analysis. P < 0.05 was considered significant.

    Search related documents:
    Co phrase search for related documents
    • atrial pressure and heart rate: 1
    • atrial pressure and hr heart rate: 1
    • atrial pressure and model analysis: 1
    • bronchial collapse and MMVD severity: 1
    • bronchial stent placement and MMVD severity: 1, 2
    • cardiac output and flow velocity: 1, 2, 3, 4
    • cardiac output and heart rate: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • cardiac output and hr heart rate: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
    • clinical benefit and flow velocity: 1
    • clinical benefit and heart rate: 1, 2, 3, 4
    • clinical benefit and hr heart rate: 1, 2
    • degenerative valve disease and different observer: 1
    • exclusion criterion and heart rate: 1
    • flow velocity and heart rate: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
    • flow velocity and hr heart rate: 1, 2, 3, 4
    • flow velocity and MMVD severity: 1
    • heart rate and hr heart rate: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • heart rate and lateral recumbency: 1, 2, 3
    • heart rate and mixed ANOVA model analysis: 1, 2